Table 2. Univariate analysis showing the prognostic significance of clinicopathologic features on the outcomes of the 184 patients recruited in this study.
Variables | 5-year OS | 5-year LRC | 5-year DFS | |||
---|---|---|---|---|---|---|
% | P | % | P | % | P | |
Age | 0.582 | 0.293 | 0.99 | |||
≤60 | 86.2 | 97.2 | 80.3 | |||
>60 | 82.8 | 92.1 | 79.1 | |||
Stage (AJCC) | 0.021 | 0.725 | 0.035 | |||
91.4 | 96.5 | 86.7 | ||||
79.4 | 94.6 | 73.6 | ||||
N stage | 0.002 | 0.125 | <0.001 | |||
N0 | 91.4 | 96.5 | 86.7 | |||
N1 | 85.2 | 97.2 | 83.3 | |||
N2 | 69.2 | 89.9 | 56.0 | |||
T stage | 0.712 | 0.807 | 0.636 | |||
T1–T2 | 77.6 | 91.7 | 80.5 | |||
T3–T4 | 86.6 | 96.7 | 80.1 | |||
Tumor grade | 0.05 | 0.958 | 0.079 | |||
Well | 83.1 | 94.7 | 78.2 | |||
Moderately | 87.9 | 96.3 | 83.3 | |||
Poorly | 71.1 | 91.7 | 64.9 | |||
Tumor nodules | 0.015 | 0.295 | 0.056 | |||
No | 87.8 | 95.9 | 82.1 | |||
Yes | 70.1 | 93.0 | 68.8 |
Abbreviations: OS, overall survival; LRC, locoregional control; DFS, disease-free survival; AJCC, American Joint Committee on Cancer, 6th edition